Guardant Health, Inc. (GH)
Stock Price:
$106.72 USD
-2.96 (-2.70%)
Updated Oct 30, 2020 3:59 PM EDT - Market closed
Key Info
| Market Cap |
10.63B |
| Revenue (ttm) |
257.59M |
| Net Income (ttm) |
-120.37M |
| Shares Out |
99.62M |
| EPS (ttm) |
-1.27 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$106.72 |
| Previous Close |
$109.68 |
| Change ($) |
-2.96 |
| Change (%) |
-2.70% |
| Day's Open |
108.98 |
| Day's Range |
105.30 - 109.60 |
| Day's Volume |
569,025 |
| 52-Week Range |
55.90 - 114.33 |
More Stats
| Market Cap |
10.63B |
| Enterprise Value |
9.73B |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
99.62M |
| Float |
85.46M |
| EPS (basic) |
-1.28 |
| EPS (diluted) |
-1.27 |
| FCF / Share |
-1.04 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.35M |
| Short Ratio |
1.70 |
| Short % of Float |
2.75% |
| Beta |
0.50 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
41.27 |
| PB Ratio |
9.88 |
| Revenue |
257.59M |
| Operating Income |
-132.97M |
| Net Income |
-120.37M |
| Free Cash Flow |
-100.21M |
| Net Cash |
896.71M |
| Net Cash / Share |
9.00 |
| Gross Margin |
55.77% |
| Operating Margin |
-51.62% |
| Profit Margin |
-46.70% |
| FCF Margin |
-38.90% |
| ROA |
-7.47% |
| ROE |
-11.52% |
| ROIC |
-14.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (10)
| Buy |
10 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$116.78*
(9.43% upside)
Low
100
Current: $106.72
High
130
Target: 116.78
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 214 | 90.64 | 49.84 | 25.25 |
| Revenue Growth | 136.52% | 81.85% | 97.4% | - |
| Gross Profit | 144 | 47.43 | 18.22 | 3.13 |
| Operating Income | -82.37 | -92.94 | -76.61 | -43.85 |
| Net Income | -75.65 | -85.06 | -83.22 | -46.14 |
| Shares Outstanding | 90.60 | 30.40 | 12.58 | 13.05 |
| Earnings Per Share | -0.84 | -2.80 | -7.07 | -3.53 |
| Operating Cash Flow | -47.13 | -72.19 | -72.24 | -36.71 |
| Capital Expenditures | -21.22 | -20.20 | -6.68 | -1.77 |
| Free Cash Flow | -68.35 | -92.39 | -78.92 | -38.48 |
| Cash & Equivalents | 523 | 419 | 221 | 95.26 |
| Total Debt | 33.26 | - | 0.66 | 17.04 |
| Net Cash / Debt | 490 | 419 | 221 | 78.22 |
| Assets | 963 | 587 | 343 | 117 |
| Liabilities | 115 | 62.45 | 34.33 | 36.87 |
| Book Value | 798 | 483 | 309 | 79.70 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Guardant Health, Inc. |
| Country |
United States |
| Employees |
622 |
| CEO |
Helmy Eltoukhy |
Stock Information
| Ticker Symbol |
GH |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: GH |
| IPO Date |
October 4, 2018 |
Description
Guardant Health, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. The company has collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.